Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Its important to note that alternative therapies should never replace traditional medical treatment and should be discussed with a healthcare provider
AWARD-11 was a randomized, controlled trial that evaluated the efficacy and safety of Trulicity at multiple doses
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with comorbidities The medication slows gastric emptying and may cause gastrointestinal side effects including nausea and abdominal discomfort, which could indirectly affect sleep quality Weight loss achieved through Wegovy may improve obesity-related sleep disorders such as obstructive sleep apnoea Practical strategies include eating final meals 34 hours before bedtime, maintaining consistent sleep schedules, and managing gastrointestinal side effects Seek medical advice if sleep disturbances persist beyond 23 weeks, cause excessive daytime sleepiness, or are accompanied by severe symptoms Table of Contents Understanding Wegovy and Its Effects on Sleep Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
During the melatonin-dominant night phase
Coverage and cost for Ozempic will vary depending on your insurance plan
References Pohlandt, F
